Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Non-severe SARS-CoV-2 Outpatients With Herbal Compound Xagrotin, Phase 3

NCT05222425 is registered in ClinicalTrials.gov with Biomad AS as lead sponsor.

NCT NCT05222425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05222425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Non-severe SARS-CoV-2 Outpatients With Herbal Compound Xagrotin, Phase 3
Lead sponsor
Biomad AS
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2022
Completion date
December 7, 2022
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2